{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:50:45Z","timestamp":1788263445657,"version":"build-2803163510"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,13]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Pomalidomide is an immunomodulatory imide drug used in multiple myeloma and in Kaposi sarcoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 72-years-old male, treated for multiple myeloma with dexamethasone, pomalidomide and daratumumab, presented dyspnea, hypoxemia, biological inflammatory syndrome, ground glass opacities on computed tomography scan (CT-scan) and lymphocytic and eosinophilic alveolitis, with no specific cytologic or microbiological findings, 2 months after pomalidomide initiation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention and outcome:<\/jats:title>\n            <jats:p>Antibiotics were started after bronchoscopy. No improvement was noted in dyspnea and biological inflammatory syndrome after 5 days of treatment. Pomalidomide was then discontinued, with continuation of Daratumumab-Dexamethasone, resulting in a rapid recovery of symptoms and CT-scan anomalies. No recurrence of dyspnea was observed during the 15 months of follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Pomalidomide-induced lung injury<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Pomalidomide-induced lung injury is a rare and serious adverse event that can occur early after Pomalidomide introduction. As pomalidomide use is increasing, the identification of drug toxicity as a possible cause of lung injury appears important. We report a rapid recovery of symptoms and CT-scan anomalies after pomalidomide discontinuation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032473","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:56:10Z","timestamp":1673657770000},"page":"e32473","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Pomalidomide-induced lung injury: A case report"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8975-7111","authenticated-orcid":false,"given":"Alexandre","family":"Vivien","sequence":"first","affiliation":[{"name":"Department of Respiratory Diseases, Reims University Hospital, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Ancel","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, Reims University Hospital, Reims, France"},{"name":"INSERM UMR-S 1250 \u201cPathologies Pulmonaires Et Plasticit\u00e9 Cellulaire,\u201d University of Reims Champagne-Ardenne, Reims, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Godet","sequence":"additional","affiliation":[{"name":"Department of Hematology, Reims University Hospital, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Dury","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, Reims University Hospital, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne-Marie","family":"Perotin","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, Reims University Hospital, Reims, France"},{"name":"INSERM UMR-S 1250 \u201cPathologies Pulmonaires Et Plasticit\u00e9 Cellulaire,\u201d University of Reims Champagne-Ardenne, Reims, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetan","family":"Deslee","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, Reims University Hospital, Reims, France"},{"name":"INSERM UMR-S 1250 \u201cPathologies Pulmonaires Et Plasticit\u00e9 Cellulaire,\u201d University of Reims Champagne-Ardenne, Reims, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Launois","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, Reims University Hospital, Reims, France"},{"name":"INSERM UMR-S 1250 \u201cPathologies Pulmonaires Et Plasticit\u00e9 Cellulaire,\u201d University of Reims Champagne-Ardenne, Reims, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40265-013-0047-x","article-title":"Pomalidomide: first global approval.","volume":"73","author":"Elkinson","year":"2013","journal-title":"Drugs"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1200\/JCO.2016.69.3812","article-title":"Pomalidomide for symptomatic Kaposi\u2019s sarcoma in people with and without HIV infection: a phase I\/II study.","volume":"34","author":"Polizzotto","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2147\/DDDT.S115456","article-title":"Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.","volume":"11","author":"R\u00edos-Tamayo","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","article-title":"Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.","volume":"116","author":"G\u00f6rg\u00fcn","year":"2010","journal-title":"Blood"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma.","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","article-title":"Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.","volume":"22","author":"Schey","year":"2004","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e28756","DOI":"10.1002\/pbc.28756","article-title":"Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: a pediatric brain tumor consortium trial.","volume":"68","author":"Fangusaro","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.clml.2019.04.003","article-title":"Pomalidomide-based regimens for treatment of relapsed and relapsed\/refractory multiple myeloma: systematic review and meta-analysis of phase 2 and 3 clinical trials.","volume":"19","author":"Mushtaq","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma.","volume":"132","author":"Tun","year":"2018","journal-title":"Blood"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12185-011-0997-2","article-title":"Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide.","volume":"95","author":"Iino","year":"2012","journal-title":"Int J Hematol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1378\/chest.06-1734","article-title":"Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.","volume":"131","author":"Thornburg","year":"2007","journal-title":"Chest"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000305213","article-title":"A case of lenalidomide-induced hypersensitivity pneumonitis.","volume":"33","author":"Lerch","year":"2010","journal-title":"Onkologie"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1378\/chest.10-2082","article-title":"Acute lung toxicity related to pomalidomide.","volume":"140","author":"Geyer","year":"2011","journal-title":"Chest"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MAJ.0000000000000532","article-title":"Pomalidomide-induced pulmonary toxicity in multiple myeloma.","volume":"350","author":"Modi","year":"2015","journal-title":"Am J Med Sci"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.5588\/ijtld.18.0244","article-title":"Pulmonary toxicity associated with pomalidomide.","volume":"22","author":"Gajic","year":"2018","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"487","DOI":"10.5530\/jyp.2018.10.106","article-title":"Pomalidomide related pulmonary toxicity: a case report.","volume":"10","author":"Kumar","year":"2018","journal-title":"J Young Pharm"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MJT.0000000000000870","article-title":"Pomalidomide-associated pulmonary toxicity.","volume":"28","author":"Icard","year":"2021","journal-title":"Am J Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:37:50Z","timestamp":1746326270000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032473","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}